Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9643

Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies  

Chen, Wei (Faculty of Environmental Science and Engineering, Kunming University of Science and Technology)
Yang, Heng (Yunnan Tropical and Subtropical Animal Virus Diseases Laboratory, Yunnan Animal Science and Veterinary Institute)
Tang, Wen-Ru (Faculty of Medicine, Kunming University of Science and Technology)
Feng, Shi-Jun (Faculty of Medicine, Kunming University of Science and Technology)
Wei, Yun-Lin (Faculty of Life Science and Technology, Kunming University of Science and Technology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9643-9647 More about this Journal
Abstract
Background: Several studies have been performed to investigate the association of the HER2 Ile655Val polymorphism and breast cancer risk. However, the results were inconsistent. To understand the precise relationship, a meta-analysis was here conducted. Materials and Methods: A search of PubMed conducted to investigate links between the HER2 Ile655Val polymorphism and breast cancer, identified a total of 32 studies, of which 29, including 14,926 cases and 15,768 controls, with odds ratios (ORs) with 95% confidence intervals were used to assess any association. Results: In the overall analysis, the HER2 Ile655Val polymorphism was associated with breast cancer in an additive genetic model (OR=1.136, 95% CI 1.043-1.239, p=0.004) and in a dominant genetic (OR=1.118, 95% CI 1.020-1.227, p=0.018), while no association was found in a recessive genetic model. On subgroup analysis, an association with breast cancer was noted in the additive genetic model (OR=1.111, 95% CI: 1.004-1.230, p=0.042) for the Caucasian subgroup. No significant associations were observed in Asians and Africans in any of the genetic models. Conclusions: In summary, our meta-analysis findings suggest that the HER2 Ile655Val polymorphism is marginally associated with breast cancer susceptibility in worldwide populations with additive and dominant models, but not a recessive model.
Keywords
HER2; polymorphism; breast cancer; meta-analysis; additive; dominant; recessive; models;
Citations & Related Records
연도 인용수 순위
  • Reference
1 AbdRaboh NR, Shehata HH, Ahmed MB, et al (2013). HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. Dis Markers, 34, 407-17.   DOI
2 Akisik E, Dalay N (2004). Estrigen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol, 76, 260-3.   DOI
3 An HJ, Kim NK, Oh D, et al (2005). Her2V655 genotype and breast cancer progression in Korean women. Pathol Int, 55, 48-52.   DOI
4 Benusiglio PR, Pharoah PD, Smith PL, et al (2006). HapMapbased study of the 17p21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer, 95, 1689-95.   DOI
5 Cooke T, Reeves J, Lanigan A, et al (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol, 12, 23-8.
6 Cox DG, Hanknson SE, Hunter DJ (2005). The ERBB2/HER2/ neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genom, 15, 447-50.   DOI
7 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
8 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-anaysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
9 Fleishman SJ, Schlessinger J, Ben-Tal N (2002). A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA, 99, 15937-40.   DOI
10 Frank B, Hemminki K, Wirtenberger M, et al (2005). The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis, 26, 643-7.
11 Kalemi TG, Lambropoulos AF, Gueorguiev M, et al (2005). The association of P53 mutations and P53 codon 72, Her2 codon 655 and MTHFE C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett, 222, 57-65.   DOI
12 Kallel I, Kharrat N, Al-fadhly S, et al (2010). HER2 polymorphisms and breast cancer in Tunisian women. Genet Test Mol Bioma, 14, 29-35.   DOI
13 Kamali-Sarvestani E, Talei AR, Merat A (2004). Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett, 215, 83-7.   DOI
14 Kara N, Karakus N, Ulusoy AN, et al (2010). P53 codon 72 and HER2 codon 655 polymorphisms in turkish breast cancer patients. DNA Cell Biol, 29, 387-92.   DOI
15 Keshava C, McCanlies EC, Keshaca N, et al (2001). Distribution of HER2 (V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett, 173, 37-41.   DOI
16 Lee SC, Hou MF, Hsieh PC, et al (2008). A case-control study of the HER2 Ile655val polymorphism and risk of breast cancer in Taiwan. Clin Biochem, 41, 121-5.   DOI
17 Lemieux J, Diorio C, Cote MA, et al (2013). Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res, 33, 2569-76.
18 Linos E, Rosner BA, Linos K (2008). Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer I, 100, 1352-9.   DOI   ScienceOn
19 Marie-Genica C (2010). Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Tr, 120, 726-36.
20 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
21 Millikan R, Eaton A, Worley K, et al (2003). HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Tr, 79, 355-64.   DOI
22 Montgomery KG, Gertig DM, baxter SW, et al (2003). The HER2 I665V polymorphism and risk of breast cancer in women
23 Mutluhan H, Akbas E, Erdogan NE, et al (2008). The influence of HER2 genotypes as molecular markers on breast cancer outcome. DNA Cell Biol, 27, 575-9.   DOI
24 Nakajima M, Sawada H, Yamada Y, et al (1999). The prognostic significance of amplification and overexpression of c-met and c-erB-2 in human gastric carcinomas. Cancer, 85, 1894-902.   DOI
25 Naidu R, Yip CH, Taib NA (2008). Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma, 55, 87-95.
26 Nelson SE, Gould MN, Hampton JM, et al (2005). A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res, 7, 357-64.   DOI
27 Ozturk O, Canbay E, Kahraman OT, et al (2013). HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer. Mol Biol Rep, 40, 1813-8.   DOI
28 Pinto D, Vasconcelos A, Costa S, et al (2004). HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev, 13, 177-81.   DOI
29 Papadopoulou E, Simoupoulos K, Tripsianis G, et al (2007). Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma, 54, 365-73.
30 Papewalis J, Nikitin AY, Rajewsky MF (1991). G to A polymorphism at amino acid codon 655 of the human erbB-2/ HER2 gene. Nucleic Acids Res, 19, 5452.
31 Qu s, Cai Q, Gao YT, et al (2008). ERBB2 genetic polymorphism and breast cancer risk in Chinese women: A population-based case-control study. Breast cancer Res Tr, 110, 169-76.   DOI   ScienceOn
32 Roca L, Dieras V, Roche H, et al (2013). Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial. Breast Cancer Res Tr, 139, 789-800.   DOI
33 Ross JS, Fletcher JA, Linette GP, et al (2003). The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 8, 307-25.   DOI   ScienceOn
34 Siegel R, Naishadam D, Jemal A (2012). Cancer statistics. CACancer J Clin, 62, 10-29.   DOI   ScienceOn
35 Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.   DOI   ScienceOn
36 Tommasi S, Fedele V, Lacalamita R, et al (2007). 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCAL alterations. Cell Oncol, 29, 241-8.
37 Takano K, Ogasahara K, Kaneda H, et al (1995). Contribution of hydrophobic residues to the stability of human lysozyme: Calormetric studies and X-ray structural analysis of the five isoleucine to valine. J Mol Biol, 254, 62-76.   DOI
38 Tao WY, Wang CY, Han R, et al (2009). Her2 condon 655 Polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Tr, 114, 371-6.   DOI
39 Tommasi S, Fedele V, Lacalamita R, et al (2004). Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett, 209, 215-22.   DOI
40 Uzan C, Darai E, Valent A, et al (2009). Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch, 454, 525-9.   DOI
41 Wang HW, Liu LT, Lang ZF, et al (2013). Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects. J Surg Oncol, 108, 335-6.   DOI
42 Xie D, Shu XQ, Deng ZL, et al (2000). Population-based, casecontrol study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst, 92, 412-17.   DOI
43 Zhang M, Guo LL, Cheng Z, et al (2011). A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women. Oncol Lett, 2, 653-8.
44 Ziegler RG, Anderson WF, Gail MH (2008). Increasing breast cancer incidence in China: the numbers add up. J Natl Cancer I, 100, 1339-41.   DOI   ScienceOn
45 Zubor P, Vojvodova A, Danko J, et al (2006). HER-2 [Ile655Val] polymorphism in association with breast cancer risk: A population-based case-control study in Slovakia. Neoplasma, 53, 49-55.